Literature DB >> 3418786

Identification of a signal in a murine retrovirus that is sufficient for packaging of nonretroviral RNA into virions.

M A Adam1, A D Miller.   

Abstract

A region near the 5' end of Moloney murine leukemia virus (MoMLV) is required for packaging of viral RNA into virions. Retroviral vectors based on MoMLV have been constructed that are also efficiently packaged into virions despite removal of most of the interior region of the parental virus. To further localize sequences which are sufficient for packaging, we inserted various fragments from an MoMLV-based retroviral vector into a nonretroviral transcription unit, transfected these constructs into retrovirus-packaging cells, and measured packaging of RNA transcribed from these constructs into virions. Transcripts from some of these constructs were packaged at least as well as those from the parental vector or MoMLV itself. Sequences extending into the gag region, but not the long terminal repeat or tRNA-binding sequences, were required for efficient RNA packaging. RNAs transcribed from constructs which did not contain an insert, or in which the orientation of the insert was reversed, were not packaged at detectable levels. These studies define sequences which are necessary and sufficient for encapsidation of murine leukemia virus RNA into virions.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3418786      PMCID: PMC253525          DOI: 10.1128/JVI.62.10.3802-3806.1988

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  18 in total

1.  A new technique for the assay of infectivity of human adenovirus 5 DNA.

Authors:  F L Graham; A J van der Eb
Journal:  Virology       Date:  1973-04       Impact factor: 3.616

2.  Construction of a retrovirus packaging mutant and its use to produce helper-free defective retrovirus.

Authors:  R Mann; R C Mulligan; D Baltimore
Journal:  Cell       Date:  1983-05       Impact factor: 41.582

3.  Characterization of a Rous sarcoma virus mutant defective in packaging its own genomic RNA: biochemical properties of mutant TK15 and mutant-induced transformants.

Authors:  T Koyama; F Harada; S Kawai
Journal:  J Virol       Date:  1984-07       Impact factor: 5.103

4.  Two base changes restore infectivity to a noninfectious molecular clone of Moloney murine leukemia virus (pMLV-1).

Authors:  A D Miller; I M Verma
Journal:  J Virol       Date:  1984-01       Impact factor: 5.103

Review 5.  Form and function of retroviral proviruses.

Authors:  H E Varmus
Journal:  Science       Date:  1982-05-21       Impact factor: 47.728

6.  A new dominant hybrid selective marker for higher eukaryotic cells.

Authors:  F Colbère-Garapin; F Horodniceanu; P Kourilsky; A C Garapin
Journal:  J Mol Biol       Date:  1981-07-25       Impact factor: 5.469

7.  Identification of a sequence likely to be required for avian retroviral packaging.

Authors:  T Pugatsch; D W Stacey
Journal:  Virology       Date:  1983-07-30       Impact factor: 3.616

8.  Enhancing the efficiency of DNA-mediated gene transfer in mammalian cells.

Authors:  C M Corsaro; M L Pearson
Journal:  Somatic Cell Genet       Date:  1981-09

9.  Avian oncovirus mutant (SE21Q1b) deficient in genomic RNA: characterization of a deletion in the provirus.

Authors:  P R Shank; M Linial
Journal:  J Virol       Date:  1980-11       Impact factor: 5.103

10.  Encapsidation sequences for spleen necrosis virus, an avian retrovirus, are between the 5' long terminal repeat and the start of the gag gene.

Authors:  S Watanabe; H M Temin
Journal:  Proc Natl Acad Sci U S A       Date:  1982-10       Impact factor: 11.205

View more
  89 in total

1.  An Mpsi-containing heterologous RNA, but not env mRNA, is efficiently packaged into avian retroviral particles.

Authors:  J D Banks; B O Kealoha; M L Linial
Journal:  J Virol       Date:  1999-11       Impact factor: 5.103

2.  The 17 nucleotides downstream from the env gene stop codon are important for murine leukemia virus packaging.

Authors:  S S Yu; J M Kim; S Kim
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

3.  Development of minimal lentivirus vectors derived from simian immunodeficiency virus (SIVmac251) and their use for gene transfer into human dendritic cells.

Authors:  P E Mangeot; D Nègre; B Dubois; A J Winter; P Leissner; M Mehtali; D Kaiserlian; F L Cosset; J L Darlix
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

4.  Unusually high frequency of reconstitution of long terminal repeats in U3-minus retrovirus vectors by DNA recombination or gene conversion.

Authors:  P Olson; H M Temin; R Dornburg
Journal:  J Virol       Date:  1992-03       Impact factor: 5.103

5.  Femtomole SHAPE reveals regulatory structures in the authentic XMRV RNA genome.

Authors:  Jacob K Grohman; Sumith Kottegoda; Robert J Gorelick; Nancy L Allbritton; Kevin M Weeks
Journal:  J Am Chem Soc       Date:  2011-11-29       Impact factor: 15.419

6.  A mutant of human immunodeficiency virus with reduced RNA packaging and abnormal particle morphology.

Authors:  F Clavel; J M Orenstein
Journal:  J Virol       Date:  1990-10       Impact factor: 5.103

7.  Production of high-titer helper virus-free retroviral vectors by cocultivation of packaging cells with different host ranges.

Authors:  C M Lynch; A D Miller
Journal:  J Virol       Date:  1991-07       Impact factor: 5.103

8.  Improved retroviral vectors for gene transfer and expression.

Authors:  A D Miller; G J Rosman
Journal:  Biotechniques       Date:  1989-10       Impact factor: 1.993

9.  An integration-defective U5 deletion mutant of human immunodeficiency virus type 1 reverts by eliminating additional long terminal repeat sequences.

Authors:  E Vicenzi; D S Dimitrov; A Engelman; T S Migone; D F Purcell; J Leonard; G Englund; M A Martin
Journal:  J Virol       Date:  1994-12       Impact factor: 5.103

10.  Mutational analysis of cis-acting packaging signals in human immunodeficiency virus type 1 RNA.

Authors:  J Luban; S P Goff
Journal:  J Virol       Date:  1994-06       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.